Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy
16 November 2023 - 12:00AM
Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a
clinical-stage TechBio company specializing in developing
AI-Immunology™ powered vaccines, presents for the first time its AI
model designed to predict patient responses to cancer immunotherapy
at the Biomarkers & Precision Oncology Europe conference in
Berlin, Germany.
The broad use of immunotherapy drugs called
checkpoint inhibitors has significantly advanced cancer treatment.
However, their effectiveness is limited, with success rates at
approximately 15% for most cancers. This inherent challenge
emphasizes the critical need for a reliable approach to identify
the patients who will benefit from standard-of-care cancer
immunotherapy. This can improve patient outcomes and reduce
healthcare costs.
“When I joined Evaxion, I was inspired by the
wealth of opportunities to improve the lives of patients facing
life-threatening diseases. Building upon Evaxion’s core
competencies, we have developed an AI model that shows promising
results in predicting patients at risk of advancing into
progressive disease while undergoing checkpoint inhibitor therapy,
enabling earlier intervention with alternative treatments,”
commented Christian Kanstrup, Evaxion’s Chief Executive
Officer.
Christian continued, “We set out to improve
patient outcomes and address the growing healthcare burden by
developing our first checkpoint inhibitor response predictor model.
The model relies on our unique AI-Immunology™ platform, builds upon
our existing core competencies and is part of the “Responder” leg
of our corporate strategy. Today’s presentation marks our first
step on our journey towards this goal, and we will develop a
commercial offering where collaboration and partnerships will be
instrumental in achieving our vision for a more cost-effective and
efficient healthcare system as well as improving patient
outcomes.”
About EVAXION Evaxion
Biotech A/S is a pioneering TechBio company based upon its AI
platform: AI-Immunology™. Evaxion’s proprietary and scalable AI
prediction models harness the power of artificial intelligence to
decode the human immune system and develop novel immunotherapies
for cancer, bacterial diseases, and viral infections. Based upon
AI-Immunology™, Evaxion has developed a clinical-stage oncology
pipeline of novel personalized vaccines and a preclinical
infectious disease pipeline in bacterial and viral diseases with
high unmet medical needs. Evaxion is committed to transforming
patients’ lives by providing innovative and targeted treatment
options. For more information about Evaxion and its groundbreaking
AI-Immunology™ platform and vaccine pipeline, please visit our
website.
Forward-Looking
Statement This announcement contains
forward-looking statements within the meaning of Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The
words “target,” “believe,” “expect,” “hope,” “aim,” “intend,”
“may,” “might,” “anticipate,” “contemplate,” “continue,”
“estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can
have,” “likely,” “should,” “would,” “could,” and other words and
terms of similar meaning identify forward-looking
statements. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
factors, including, but not limited to, risks related to: our
financial condition and need for additional capital; our
development work; cost and success of our product development
activities and preclinical and clinical trials; commercializing any
approved pharmaceutical product developed using our AI platform
technology, including the rate and degree of market acceptance of
our product candidates; our dependence on third parties, including
for conduct of clinical testing and product manufacture; our
inability to enter into partnerships; government regulation;
protection of our intellectual property rights; employee matters
and managing growth; our ADSs and ordinary shares, the impact
of international economic, political, legal, compliance, social and
business factors, including inflation, and the effects on
our business from the worldwide ongoing COVID-19 pandemic and
the ongoing conflict in the region
surrounding Ukraine and Russia and the Middle
East; and other uncertainties affecting our business
operations and financial condition. For a further discussion
of these risks, please refer to the risk factors included in our
most recent Annual Report on Form 20-F and other
filings with the U.S. Securities and Exchange Commission
(SEC), which are available
at www.sec.gov. We do not assume any
obligation to update any forward-looking statements except as
required by law.
Contact Information
Evaxion Biotech A/S
Christian Kanstrup
Chief Executive Officer
cka@evaxion-biotech.com
Source: Evaxion Biotech
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From Apr 2024 to May 2024
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From May 2023 to May 2024